Allogene, a new biotech founded by former Kite Pharma CEO Arie Belldegrun and his top management team is to accelerate development of “off-the-shelf” CAR-T cancer therapies, taking over fro
Cellectis are leaders in developing 'off the shelf' CAR-Ts which promise a cheaper and simpler alternative to the first-generation therapies - but progress has been slowed by setbacks and s
The FDA has said Cellectis can restart trials of its ‘off-the-shelf’ CAR-T cancer immunotherapy, after revising protocols in a trial that killed one patient and left another with life-threa
Cellectis’ 'off the shelf' CAR-T cancer therapy has hit a major setback after the first patient treated in a phase 1 study died, and the first patient treated in another developed life-thr
It may seem that Servier and Pfizer are light years behind rivals Kite and Novartis in their bid to develop a CAR-T cancer immunotherapy, as a phase 1 study is just beginning.
If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho